company overview - agc · company overview p.3 2. the agc group medium-term management plan “agc...

42
Company Overview May, 2020

Upload: others

Post on 26-May-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Company Overview

May, 2020

Page 2: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Contents

1. Company Overview P.3

2. The AGC Group Medium-term Management Plan

“AGC plus-2020” P.7

3. Measures for core business P. 13

4. Progress of Strategic Business P. 20

5. Shareholder Return P.28

6. Outlook for FY2020 P.30

7. Appendix P.36

©AGC Inc. 2

Page 3: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

1. Company Overview

©AGC Inc. 3

Page 4: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Architectural GlassSales 352.7 bn yen

Business Overview

AGC Group (Net sales 1,518.0 billion yen, Operating profit 101.6 billion yen)

-Float flat glass-Figured glass-Polished wired glass-Low-E glass-Decorative glass-Fabricated glass for architectural use(Heat Insulating/shielding glass, Disaster-resistant/Security glass, Fire-resistant glass, etc.)

-Automotive glass-Cover glass for car- mounted displays

Automotive GlassSales 388.3 bn yen

-Polyvinyl chloride-Vinyl chloride monomer-Caustic soda-Urethane

-Fluorinated resins-Water and oil repellents-Gases-Solvents-Iodine-related products

Fluorochemicals& specialty chemicalsSales 119.9 bn yen

Chlor-alkali & urethaneSales 292.8 bn yen

-Semiconductor process materials-Optoelectronics materials-Printed circuit boat materials-Lighting glass products-Laboratory glass, etc.

DisplaySales 174.7 bn yen

Electronic MaterialsSales 90.5 bn yen

-LCD glass substrates-OLED glass substrates-Specialty glass for display applications-Display related materials-Glass for solar power system-Fabricated glass for industrial use

For the fiscal year ended December 31, 2019

-Ceramic products-Logistics and financialservices, etc.

Ceramics/OtherSales 83.2 bn yenOP 3.9 bn yen

GlassSales 742.9 bn yenOP 9.3 bn yen

ChemicalsSales 475.8 bn yen OP 63.0 bn yen

ElectronicsSales 276.7 bn yenOP 25.6 bn yen

©AGC Inc.

Life ScienceSales 61.7 bn yen

-Pharmaceutical and agrochemicalintermediates and active ingredients

(including biopharmaceuticals)

4

Page 5: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Net sales:1,518.0 billion yen OP:101.6 billion yen Group Employees: 55,600

-Architectural Glass-Automotive Glass-Electronic Materials-Fluorochemicals-Life science

-Architectural Glass-Automotive Glass-Fluorochemicals-Life science

-Architectural Glass-Automotive Glass -Display Glass -Electronic Materials-Chlor-alkali & Urethane-Life science-Ceramics

The AmericasSales: 172.6 bn yenOP: 5.5 bn yenEmployees: 5,300

EuropeSales: 338.7 bn yenOP: 15.1 bn yen

Employees: 17,100

Japan / AsiaSales: 1,006.7 bn yen OP: 121.7 bn yenEmployees: 33,200

Results of FY2019

Global Operation

©AGC Inc. 5

Page 6: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Changes in the Financial Results

6©AGC Inc.

FY2014 FY2015 FY2016 FY2017 FY2018 FY2019

Net sales 13,483 13,263 12,826 14,635 15,229 15,180

Operating profit 621 712 963 1,196 1,206 1,016

Profit for the year attributable to owners of the parents 159 429 474 692 896 444

Operating profit margin 4.6% 5.4% 7.5% 8.2% 7.9% 6.7%

Dividend per share ¥90 ¥90 ¥90 ¥105 ¥115 ¥120

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

2,000

0

3,000

6,000

9,000

12,000

15,000

18,000

[OP

, Pro

fit for th

e y

ear a

ttribu

tab

le to

ow

ners

of th

e p

are

nt]

(100 million yen)

[Net s

ale

s]

- Dividend (per share) is adjusted to reflect the 5 into 1 share consolidation implemented on 1 July 2017.- Full-year forecast for FY2020 on financial results and dividend is subject to review due to the spread of COVID-19.

Page 7: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

2. The AGC Group Medium-term management plan“AGC plus-2020”

©AGC Inc. 7

Page 8: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

AGC Group’s long-term strategy

“Vision 2025”

Establishing long-term, stable sources of earnings through the portfolio

management

・Architectural glass・Automotive glass (existing)・Essential chemicals・Performance chemicals・Display glass・Ceramics

Establishing highly profitable businesses through expansion of high

value-added businesses

・Mobility

・Electronics

・Life science

Core businesses Strategic businesses

The AGC Group’s Core Businesses will serve as solid sources of earnings, and Strategic Businesses will become growth drivers and lead further earnings growth.The AGC Group will continue being a highly profitable, leading global material and solution provider.

©AGC Inc. 8

Page 9: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

AGC plus-2020

◼ Develop high-value added businesses that do not

get affected by market fluctuations

◼ Promote growth strategies for strategic businesses

◼ Concentrate management resources in growth

regions/where we can win

◼ Achieve sustainable growth through strategic

M&As

AGC plus-2020 serves as the cornerstone toward 2025

©AGC Inc. 9

Page 10: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

©AGC Inc. 10

Achievement towards management target

OP

ROE

Strategic business

contribution ratio

D/E

FY2025 target

Long-term plan

FY2018 FY2020 targetFY2020 forecast

10.0% or

more

40% or more

0.5 or less

229.2billion yen or more

(record high)

8.0% or

more

25% or

more

0.5 or less

160.0billion yen or more

7.7%

17%

0.43

120.6billion yen

6.0%

29%

0.5 or less

120.0billion yen

FY2017

6.1%

10%

0.38

119.6billion yen

Mid-term management plan AGC plus-2020

◼ OP of strategic business expanding successfully◼ Active investments with maintaining healthy D/E ratio

Subject to

review*

*With many uncertain factors that will affect business results due to the spread of COVID-19, the figures FY2020 will be subject to review.

Page 11: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Major investment plans and timing of profit generation

©AGC Inc. 11

China:Relocation of furnace for G11 TFT glass substrates

Japan:Drastically enhance supply system for EUV mask blanks

Brazil:Launch second furnace

Europe:Improve productivity and fuel efficiency through cold repairing

Morocco: Launch new plant for automotive glass

China: Launch new plant for cover

glass for car-mounted displays

Glass

Electronics

Chemicals

2019 2020 2022~

Demark:Enhance production capacity for biopharmaceutical

Japan:Enhance GMP compliant synthetic pharmaceutical capacity

Indonesia:Enhance PVC production capacity

USA:Enhance production capacity of biopharmaceutical

2021

China:Enhance production capacity for G11

Thailand:Enhance electrolysis capacity

Indonesia:Launch new coating facility for architectural glass

◼ Investment effect generating from 2020, and gaining momentum from 2021

Japan:Enhance fluorochemical production capacity

Page 12: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Business portfolio management

©AGC Inc. 12

10% 20%

ROCE (FY2020 forecast)

Glass

Electronics

Chemicals

Electronic materials

Life Science

Chlor-alkali & Urethane

Display glass

Architectural glass

Automotive glass

◼ ROCE target: 10% or more

AGC Group consolidated

AGCGroup

Expand business scale while maintaining/improving asset efficiency

Improve profit and/or

improve asset efficiency by reducing operating capital employed

0%

Fluorochemicals& Speciality

- ROCE : (OP forecast for FY2020)/(FY2020 year end operating capital employed(Trade receivables+Inventory –Trade payables +Fixed assets)).Corporate expense is not allocated to OP forecast of each sub-segment.

- Calculated as of February 2020.

Page 13: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

©AGC Inc. 13

3. Measures for core business

Page 14: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Architectural glass:Integration of architectural glass business in Japan

©AGC Inc. 14

Source:chart made by AGC, based on the data of Japan’s Ministry of Economy, Trade and Industry

Architectural Glass shipment in Japan

◼ In order to adapt to shrinking demand in Japan, AGC and Central Glass Co., Ltd. have concluded a MOU to consider and discuss the integration of architectural glass businesses in Japan

◼ Aiming for business integration by end of 2020

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

40,000

45,000

1990 95 2000 5 10 15 20 25

(thousand unit)

Architectural Glass shipments in Japan

Shipments of architectural glass in Japan is decreasing

gradually, 1-2% annually

Number of facility and plantsfor architectural glass in Japan

AGC Central Glass

Furnace for architectural glass1 1

Coating facilities2 2

Furnacefor figured/polished glass 1 2

Basis for processed glass such as multi-layered glass 16 5

Basis for distribution32 27

Page 15: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Automotive Glass:strengthen profitability

©AGC Inc. 15

◼ Shift to high-value added products, and improve productivity in each region.

【Japan】

Improve product efficiency and reduce production cost.Expand sales of high-value added products.

【Asia】

Maintain the flexible operation system in response to demand fluctuations.

Measures

Install new facility by watching and responding to demand trend for high value added products, and for improving productivity.

Focusing on structural improvements, such as rationalization of production facilities and cost reduction, rather than expanding market share.

Europe

NorthAmerica

Japan/Asia

Region

Page 16: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Display:Enhancing capacity for G11 production

©AGC Inc. 16

◼ Correspond to demand increase in China for G11. Enhance total capacity by expanding the G11 polishing facility. Total number of furnace is managed to be the same.

Source:AGC’s estimation

0

100

200

300

400

500

600

700

2015 2016 2017 2018 2019 2020e 2021e 2022e

China26%

66%50%

TFT glass substrates demand(by region)

million ㎡/year

others

0

100

200

300

400

500

600

700

2015 2016 2017 2018 2019 2020e 2021e 2022e

22%

G10-11

TFT glass substrates(by

generation)million ㎡/year

others

Page 17: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

AGC capacityImport

Chemicals:Cholor-alkali business in Southeast Asia(1)

©AGC Inc. 17

◼ CAGR 4% growth for Chlor-alkali products in Southeast Asia◼ Enhancing capacity in Southeast Asia where robust demand

growth is expected and regional capacity is lacking.

Caustic soda market in Southeast Asia PVC market in Southeast Asia

Source:chart made by AGC, based on HIS data.

*Includes Australia and New Zealand.*Excludes Australia and New Zealand.

Supply in the regionAGC capacityImport Supply in the region

0

1,000

2,000

3,000

4,000

2015 16 17 18 19e 20e 21e 22e 23e 24e 25e

Acquisition of Vinythai

Capacity enhancement

in Vinythai

850

1,050

1,4201,640

Capacity of AGC

thousand ton/year

Caustic soda demand2015-2025eCAGR 4%

Demand *

0

1,000

2,000

3,000

4,000

2015 16 17 18 19e 20e 21e 22e 23e 24e 25e

thousand ton/year

1,200

1,760

1,000

700

400

Acquisition

of Vinythai

Capacity enhancement

in VinythaiCapacity

enhancement in Indonesia

PVC demand2015-2025eCAGR 4%

Demand *

Capacity of AGC

Page 18: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

0

200

400

600

800

1000

1200

2015.1Q

2Q 3Q 4Q

16.1Q

2Q 3Q 4Q

17.1Q

2Q 3Q 4Q

18.1Q

2Q 3Q 4Q

19.1Q

2Q 3Q 4Q

0

200

400

600

800

1,000

1,200

1,400

1,600

2015.1Q

2Q 3Q 4Q

16.1Q

2Q 3Q 4Q

17.1Q

2Q 3Q 4Q

18.1Q

2Q 3Q 4Q

19.1Q

2Q 3Q 4Q

Chemicals:Cholor-alkali business in Southeast Asia(2)

©AGC Inc. 18

◼ Stable profitability of chlor-alkali business in Southeast Asia.Decline of caustic soda market price is balanced by price decline of ethylene, which is PVC’s raw material.

Source:chart made by AGC, based on Bloomberg data

Caustic Soda Market

(US$/t)

Southeast Asia Caustic Soda Market(SE Asia Caustic Soda CFR price Weekly)

※PVC-ethylene spread = PVC market price - (ethylene market price×0.5)

PVC・Ethylene Market

(US$/t)

Southeast Asia Ethylene Market(SE Asia Ethylene CFR Spot Price Weekly)

Southeast Asia PVC market(SE Asia PVC CFR price Weekly)

PVC-ethylene spread※

Annual average

PVC-ethylene spread is in the trend of expansion.

Page 19: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Chemicals:Capacity Enhancement of fluorochemical

©AGC Inc. 19

◼ Enhancing capacity in response to demand growth for semiconductor, next-generation high-speed communications, and transportation related applications.

◼ Phase-based capacity enhancement from raw materials to various product groups, such as fluoro resins and low-GWP refrigerant/foaming agent.

Total investment approximately 70 billion JPY.

Profit contribution starting from FY2021 onward.

Examples of AGC’s high performance fluorochemical products

<Fluon® ETFE> <AMOLEA® 1224yd> <Fluon+TM EA-2000>

• superior moldability• heat resistant, chemical resistant• high light transmittance

• GWP value 1 or less• meeting environmental regulations• same performance as HFCs

• having adhesive and dispersible properties while maintaining characteristics of fluoro resin, such as electrical properties and durability

• very low transmission losses

Page 20: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

©AGC Inc. 20

4.Progress of strategic business

Page 21: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Strategic Businesses Highly profitable businesses with growth potential

Mobility Electronics Life Science

Arrival of IoT era Longer life expectancy

Evolution of transportation infrastructure Increase of global population

Building new eco-system Greater safety, security, comfort

【Changes in the macroscopic environment】

Connected cars/ Automated driving,Evolution of information display, Lighter-weight transportation means

Arrival of IoT/AI era, Next-generation high-speed communications/ Automated driving, Use of novel devices

Safe & secure medical care, Longer life expectancy, Increase of global population

Strategic Businesses

©AGC Inc. 21

Page 22: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

©AGC Inc. 22

OP(strategic business) 120 210 265 300 900

Contribution ratio 10% 17% 26% - 40%

(100m JPY)

Mobility

Electronics

Life Science

Sales of Strategic business

Life Science

・Cover glass for car-mounted

displays・New materials for mobility,

including 5G communications

・Semiconductor-related

products・Optoelectronics materials・Next-generation high-speed

communication related products

・Fluorinated products for

electronics

・Synthetic pharmaceutical

and agrochemical・Bio CDMO

Electronics

Mobility

Major products

& businesses

*

* The figures have been revised from those announced on February5, 2020.

Profit contribution of Strategic Business

◼ Limited impact from spread of COVID-19, OP growing steadily

100 million JPY

*

Page 23: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Expansion of Strategic Business

©AGC Inc. 23:FY2019

EUV mask blanks

Other semiconductor-

related materials

100 200 300

Sales (100m JPY)

Mobility

Electronics

Lifescience

CMP slurry

Fluorochemicals for electronics

Cover glass for car-mounted displays

Bio pharmaceutical

synthetic pharmaceutical and

agrochemical

Resin for fuel cell

CCL

EUV mask blanks

synthetic pharmaceutical and

agrochemical

Bio pharmaceutical

CCL

:FY2021(forecast):FY2017

◼ All business areas expanding sales

synthetic pharmaceutical and

agrochemical

Biopharmaceutical

4000

Optoelectronics materials

Optoelectronics materials

Page 24: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Cover glass for car-mounted display

©AGC Inc. 24

Used in New Lexus RX series released in 2019

New production site in China

◼ Establish new production site in China for large size/complex-shaped cover glass for car-mounted display

- mass production starting from FY2022◼ Expanding business as being the market leader for luxury car

market.

New

AGC Yokohama

Technical Center

Page 25: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Semiconductor processing materials and EUV mask blanks

©AGC Inc. 25

◼ Sales expanding in the semiconductor market, mainly in high-end consumables, in line with advances in IoT and semiconductor technologies.

◼ EUV mask blanks

- market size expanding significantly from FY2021, as further development for memory, as well as logic going forward.

- target sales for EUV mask blanks is 40 billion JPY or more in FY2025, and 50% market share.

Low-power

minisize

High efficiency

High durabilityTech

nolo

gy t

ren

d

AG

C’s

solu

tion

Synthetic quartzlens materials

Jig for semiconductor manufacturing equipment

Through Glass Vias

EUV mask blanksCMP slurry Glass substrate for semiconductor package

Page 26: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

15.4 16.4 17.6 18.7 20.0 21.4 22.8

3.84.1

4.44.8

5.25.6

6.0

19.220.5

2223.5

25.226.9

28.8

2016 2017 2018 2019e 2020e 2021e 2022e

total 7%

Life science

©AGC Inc. 26

Sales of AGC’s Life Science Business

367 449

617

750

1,000

FY2017 FY2018 FY2019 FY2020e FY2025e

(1 billion USD)

Worldwide pharmaceutical CDMO market

◼ Aim for high growth that outstrips market growth through M&As and active capacity increase.

◼ Target sales of 100 billion JPY is expected to be achieved earlier than FY2025

or more

Synthetic pharmaceutical and others 7%

Bio pharmaceutical 9%

2017-2022 CAGR (100 million JPY)

Source: Chart made by AGC based on the data from EvaluatePharma® World Preview 2017, Outlook to 2022

Page 27: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Business related to Next-generation high-speed communications

©AGC Inc. 27

◼ Expand business base by 5G related materials and solutions

For buildings/ Glass antenna for base stationsWAVEATTOCHTM

For automotive/5G glass antenna

Fluon+™EA-2000/Fluoro resin for printed-circuit board

CCL※

Development stage

2018 2019 2020

Develops a synthetic fused silica glass antenna for 5G

Acquired CCL business of Park Electrochemical

Acquired CCL business of Taconic

Capacity expansion announced

Develops flexible antenna design technology for

millimeter wave with ultra-low transmission loss

Achieved communications with 28GHz band

compatible antenna with a fast-moving vehicle

World’s first product to add cellular base station

functions to windows3.5GHz(LTE) band

Achieved communications with 28GHz band

compatible antenna with a moving vehicle in the city

Completion of development for 5G

(Sub6) glass antenna

Starting of service for 5G (Sub6) glass antenna (plan)

※CCL: Copper Clad Laminate

AGC’s solution examples(released)

Page 28: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

5. Shareholder Return

©AGC Inc. 28

Page 29: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Shareholder’s return

©AGC Inc. 29

◼ The current policy to be continued.

Specifically, we will maintain the consolidated total return of 50% or more, including share buyback. While dividend payment is to be not less than the current annual payment per share.

Dividend pershare/year

90 JPY 90 JPY 105 JPY 115 JPY 120 JPY

Consolidated total return ratio 49% 65% 56% 51% 60%

Dividend ratio 49% 44% 35% 29% 60%

Share buyback

(100m JPY)

Dividend

- With many uncertain factors that will affect business results due to the spread of COVID-19, the dividend forecast of FY2020 will be subject to review.

Page 30: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

6. Outlook for FY2020

©AGC Inc. 30

Page 31: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

FY2020erevised

1st half full-year 1st half full-year 1st half

7,375 15,180 7,500 15,500 6,500

415 1,016 500 1,200 250

762 1,070

Dividend (JPY/share) 60 120 65 130 ー

FOREX(Average) JPY/USD 110.1 109.1 107.0

JPY/EUR 124.3 122.1 117.6

Crude oil (Dubai, average) USD/BBL 65.4 63.5 40.0

FY2019 FY2020eAs of Feb 5, 2020

444

110.0

120.0

60.0

690attributable to owners of the parent

Profit for the year

Net sales

Operating profit

Profit before tax

FY2020 Outlook

31©AGC Inc.

◼ With many uncertain factors that will affect business results due to the spread of the novel coronavirus disease (COVID-19), the figures of business results forecast and the dividend forecast announced on February 5, 2020 will be under review.

◼ Forecast will be announced once reasonable estimation can be made.

◼ Based on currently available information, the forecast for the fist half of FY2020 is as follows.

Under review

Page 32: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

2Q Outlook by Segment

32©AGC Inc.

(100 million yen)

Net salesOperating

profitNet sales

Operating

profitNet sales

Operating

profit

Glass 3,752 74 2,800 ▲ 215 ▲ 952 ▲ 289

Electronics 1,246 60 1,400 170 + 154 + 110

Chemicals 2,285 262 2,200 280 ▲ 85 + 18

Ceramics/Other 404 20 400 15 ▲ 4 ▲ 5

Elimination ▲ 312 ▲ 1 ▲ 300 0 + 12 + 1

Total 7,375 415 6,500 250 ▲ 875 ▲ 165

FY2019 FY2020Change

1-2Q 1-2Qe

Page 33: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

◼ Business activity in China and Architectural glass processing operations in Europe are recovering.◼ In several businesses other than the aforementioned, shipments are expected to decline, impacted

by demand and production adjustment by customers.◼ The impact on the Glass business is particularly significant, with a significant downward trend in

earnings.

Current situation for Each Business (As of May 18, 2020)

33©AGC Inc.

Glass

Architectural Glass• Japan & Asia: There is nearly no impact in Japan. Decrease in demand is being seen in Asia due to effect of

economic stagnation.• Americas: After bottoming out in April, we expect shipments to gradually recover from May. South America

continues to adjust its operations.• Europe: With a significant decrease in demand, we drastically adjusted operations. We expect operations to

gradually recover from May onwards, with the gradual lifting of the lockdown in European countries from May.Automotive Glass• China: Operations are starting to recover and are at pre-Chinese New Year level in May.• Japan & Asia (ex. China): In Japan, we started to adjust operation in late April and is still ongoing. In

Thailand and Indonesia, we started to adjust operation drastically in April and is still ongoing.• Europe and Americas: In April, all facilities underwent a major operation adjustment, and in May, some

facilities resumed operations.

Electronics

• LCD glass substrates: shipment has not been significantly affected until now.• Specialty glass for display applications: shipments are expected to recover from 2Q as customers' operations

in China recover.• Semiconductor-related products, and optoelectronic materials: no impact on shipments and operations.

Chemicals

• Chlor-alkali & Urethane: Shipments and sales prices are falling due to the impact of the lockdown in Asian countries

• Fluorochemicals & Specialty Chemicals: Shipments of some products, such as for automotive, aircraft, and construction are down.

• Life science: Demand is strong and there is no significant impact on both shipments and operation.

Page 34: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Response to Spread of COVID-19

34©AGC Inc.

1. Measures to prevent disease infection ⚫ Priority on safety of the AGC Group’s stakeholders, including employees and their

families, and business partners, etc.⚫ Thoroughly implement measures to prevent disease infection at sites where

production activities continue.

2. Ensure liquidity in hand⚫ Adequate cash has been secured through bank loans, etc. by end of April.

Approximately 200 billion JPY cash has been accumulated compared to end of Dec. 2019.

3. Reduction of investment and expenses⚫ Continue to invest in growth business with a focus on strategic business.⚫ In other areas, try to reduce investments and cost as much as possible.

Page 35: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Response to Spread of COVID-19

35©AGC Inc.

4. Business activities

Life science

⚫ CDMO contract for Leronlimab developed by CytoDyn, which clinical trials as a COVID-19 treatment have been commenced in the United States. The company is also partnering with AdaptVac for development and manufacture of a COVID-19 vaccine. Further CDMO contracts related to COVID-19 are in progress for multiple contracts.

⚫ AGC Biologics has joined the European COVID-19 vaccine development consortium.

Other

⚫ Supply of sodium hypochlorite used in disinfectants and drinking water disinfectant.⚫ Enhance supply of polycarbonate resin for partitions to prevent splash infection, etc.

5. Local communities ⚫ Supply of protective equipment to medical institutions in Japan and overseas, as local

community activities.

Page 36: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

7. Appendix

©AGC Inc. 36

Page 37: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Our Shared Values

AGC, an everyday essential part of our world

-AGC’s unique materials and solutions make people’s lives better around the world every day-

◆ Innovation & Operational Excellence◆ Diversity◆ Environment◆ Integrity

“Never take the easy way out, but confront difficulties”OurSpirit

OurMission

Group Vision "Look Beyond"

©AGC Inc. 37

Page 38: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

:Outside directors or outside Audit & Supervisory Board Members who satisfy Company’s “Standardsfor independence of outside officers”

CEO

CFO CTO& CCO

3 outside Audit & Supervisory

Board Members

3 outside directors

Chairman of the Board of Directors

1 director who does not serve as an Executive

Officer

General meeting of shareholders

Audit & Supervisory Board; 4 auditors

1 internal Audit &

Supervisory Board Member

Report

Board of Directors;

7 directors

Nominating Committee;

5 directors

3 outside directors2 internal directors

Chairman of the committee

Compensation Committee;

5 directors

3 outside directors2 internal directors

Chairman of the committee

Mutu

al coopera

tion

Internal Audit Division

Accounting Auditor

Report

Group Corporate CSR Committee

Management Committee

Executive Officers

Compliance Committee

Information Management Council

Security Trade Control Headquarters

In-House Companies/Strategic Business Units(SBUs)

Man

ag

em

en

t overs

igh

tB

usin

ess

execu

tion

Gro

up

corp

ora

te

fun

cti

on

Bu

sin

ess

opera

tion

s f

un

cti

on

:Internal directors or internal Audit & Supervisory Board Member

Corporate Governance StructureAs of March 27, 2020

Page 39: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Consolidated Performance Trend(100million yen)

©AGC Inc. 39

FY2014 FY2015 FY2016 FY2017 FY2018 FY2019

13,483 13,263 12,826 14,635 15,229 15,180

621 712 963 1,196 1,206 1,016

▲ 181 148 ▲ 275 ▲ 57 19 ▲ 256

440 859 688 1,139 1,225 760

▲ 29 ▲ 14 ▲ 13 5 59 2

412 845 676 1,144 1,284 762

▲ 207 ▲ 382 ▲ 142 ▲ 351 ▲ 264 ▲ 207

205 463 534 793 1,020 555

159 429 474 692 896 444

46 34 59 101 124 111

4.6% 5.4% 7.5% 8.2% 7.9% 6.7%

1.4% 3.9% 4.3% 6.1% 7.7% 3.9%

JPY/USD 105.9 121.1 108.8 112.2 110.4 109.1

JPY/EUR 140.4 134.3 120.3 126.7 130.4 122.1

63.569.4

ROE

FOREX

(Average)

$/BBL (Dubai)Crude Oil

(Average)96.5 50.9 41.5 53.2

Operating profit margin

Operating profit

Other income (expenses)

Business profit

Finance income (costs)

Net sales

Profit before tax

Income tax expenses

Profit for the year

Profit for the year attributable to

owners of the parent

Profit for the year attributable to

non-controlling interests

Page 40: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Performance by Business Segment (100million yen)

©AGC Inc. 40

Sales FY2014 FY2015 FY2016 FY2017 FY2018 FY2019

Glass 6,863 6,929 6,800 7,351 7,575 7,429

Electronics 3,197 2,886 2,581 2,624 2,526 2,767

Chemicals 3,172 3,185 3,166 4,376 4,844 4,758

Ceramics/Other 808 681 708 754 790 832

Elimination ▲ 557 ▲ 418 ▲ 429 ▲ 470 ▲ 506 ▲ 606

Consolidated total 13,483 13,263 12,826 14,635 15,229 15,180

Operating profit FY2014 FY2015 FY2016 FY2017 FY2018 FY2019

Glass ▲ 2 130 318 271 225 93

Electronics 362 290 250 273 240 256

Chemicals 241 305 400 637 711 630

Ceramics/Others 11 ▲ 16 ▲ 2 14 28 39

Elimination 2 1 ▲ 3 1 0 0

Consolidated total 621 712 963 1,196 1,206 1,016

Page 41: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

Consolidated Statements of Cash Flows

(100million yen)

©AGC Inc. 41

FY2014 FY2015 FY2016 FY2017 FY2018 FY2019

412 845 676 1,144 1,284 762

1,372 1,374 1,218 1,282 1,217 1,434

36 110 121 ▲ 150 ▲ 270 ▲ 166

▲ 461 ▲ 457 22 ▲ 242 ▲ 338 ▲ 111

1,358 1,872 2,036 2,035 1,893 1,919

▲ 1,088 ▲ 1,160 ▲ 1,136 ▲ 2,096 ▲ 1,945 ▲ 1,826

270 712 900 ▲ 61 ▲ 52 93

▲ 789 ▲ 151 ▲ 238 314 544 113

▲ 162 ▲ 208 ▲ 208 ▲ 219 ▲ 249 ▲ 266

4 5 ▲ 18 ▲ 283 ▲ 209 ▲ 20

▲ 947 ▲ 354 ▲ 465 ▲ 187 87 ▲ 173

46 ▲ 6 ▲ 11 39 ▲ 64 ▲ 17

▲ 630 352 425 ▲ 209 ▲ 29 ▲ 97

Effect of exchange rate changes on

cash and cash equivalents

Net increase(decrease) in cash and

cash equivalents

Cash flows from investing activities

Free cash flow

Cash flows from financing activities

 Changes in interest-bearing debt

 Dividends paid

 Others

 

Cash flows from operating activities

 others

 Increase (decrease) in working capital

 Depreciation and amortization expense

 Profit before tax

Page 42: Company Overview - AGC · Company Overview P.3 2. The AGC Group Medium-term Management Plan “AGC plus-2020” P.7 3. Measures for core business P. 14 ... -Pharmaceutical and agrochemical

END

■This material is solely for information purposesand should not be construed as a solicitation.Although this material (including the financialprojections) has been prepared usinginformation we currently believe reliable, AGCdoes not take responsibility for any errors andomissions pertaining to the inherent risks anduncertainties of the material presented.

■We ask that you exercise your own judgmentin assessing this material. AGC is notresponsible for any losses that may arise frominvestment decisions based on the forecastsand other numerical targets contained herein.

Copyright AGC Inc.

Disclaimer

No duplication or distribution without prior consent of AGC Inc.